Intensity Therapeutics
INTS
20 hedge funds and large institutions have $6.65M invested in Intensity Therapeutics in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0.02% more ownership
Funds ownership: 0.49% → 0.51% (+0.02%)
9% less funds holding
Funds holding: 22 → 20 (-2)
19% less capital invested
Capital invested by funds: $8.23M → $6.65M (-$1.58M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
Miami,
Florida
|
+$166K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$76.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$74.3K |
| 4 |
BlackRock
New York
|
+$36.5K |
| 5 |
SL
Sentinus LLC
Oak Brook,
Illinois
|
+$24.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$77K |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$41.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.22K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
-$4.41K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$777 |
INTS Hedge Fund Activity: Q3 2024 in Review
20 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Intensity Therapeutics (INTS) for Q3 2024, worth a combined $6.65M — down 19% from $8.23M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of INTS and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was GTS Securities, opening a new position worth an estimated $166K. The largest seller was HRT Financial, exiting entirely with an estimated $77K sold.
- 20 institutional investors held Intensity Therapeutics (INTS) as of Q3 2024, down from 22 in Q2 2024.
- Funds reported $6.65M of Intensity Therapeutics stock for Q3 2024, down 19% quarter-over-quarter.
- 1 fund opened new Intensity Therapeutics positions in Q3 2024 and 3 closed out, a net change of -2 holders.
- The largest Intensity Therapeutics buyer in Q3 2024 was GTS Securities, an estimated $166K added.
- The largest Intensity Therapeutics seller in Q3 2024 was HRT Financial, an estimated $77K sold.
Based on aggregated 13F filings for Q3 2024.